Dominari Holdings Inc. (NASDAQ:DOMH – Get Free Report) was the recipient of a significant drop in short interest in January. As of January 31st, there was short interest totalling 5,800 shares, a drop of 57.7% from the January 15th total of 13,700 shares. Based on an average daily volume of 12,000 shares, the short-interest ratio is currently 0.5 days. Approximately 0.2% of the shares of the company are short sold.
Insider Transactions at Dominari
In other Dominari news, CEO Anthony Hayes bought 70,000 shares of Dominari stock in a transaction dated Wednesday, December 20th. The stock was purchased at an average price of $2.00 per share, for a total transaction of $140,000.00. Following the completion of the purchase, the chief executive officer now directly owns 98,804 shares of the company’s stock, valued at $197,608. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders acquired 95,804 shares of company stock worth $201,824 over the last quarter. Corporate insiders own 9.74% of the company’s stock.
Hedge Funds Weigh In On Dominari
A number of large investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Dominari in the second quarter valued at approximately $219,000. Geode Capital Management LLC bought a new position in shares of Dominari in the second quarter valued at approximately $126,000. Renaissance Technologies LLC purchased a new stake in Dominari in the second quarter valued at approximately $109,000. State Street Corp bought a new stake in Dominari during the second quarter valued at approximately $58,000. Finally, Citadel Advisors LLC purchased a new position in Dominari in the 2nd quarter worth approximately $52,000. 11.90% of the stock is currently owned by institutional investors.
Dominari Price Performance
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
- Five stocks we like better than Dominari
- How to invest in marijuana stocks in 7 steps
- 3 attractive stocks that insiders are buying
- How to Buy Metaverse Stock Step by Step
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to invest in blue chip stocks
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.